CMMB vs LLY · $22.2M cap vs P/E 39, rev $22.97B
Chemomab Therapeutics Ltd DRC (CMMB) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Chemomab Therapeutics Ltd DRC (CMMB) is a biotechnology company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
CMMB does not have a complete income-statement cache yet.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
CMMB currently screens at market cap $22.2M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the CMMB and LLY stock pages for the full models.
Not investment advice.